Innovative Radiopharmaceuticals for Cancer Diagnosis and Treatment

Abstract

The presented material summarizes the experience of Cancer Research Institute and Tomsk Polytechnical University team in the development of original radiopharmaceuticals (RP) for nuclear medicine. The first such unique for world nuclear medicine RP was a Thallium­199. The Thallium­199 is successfully used for breast cancer diagnosis and its lymphogenous metastasis, as well as to visualize cancer of the larynx and laryngopharynx, their relapses and for differential diagnosis of inflammatory and tumor processes of the musculoskeletal system. The great practical importance for nuclear medicine has the organization of a waste­free production of sorption and extraction generators of Technetium­-99m at the IRT­T TPU nuclear research reactor, as well as the creation of a fully automated 99mTc module operating on a waste­ free technology. The development of the 99mTc­Alotech for targeting imaging of sentinel lymph nodes (SLN) has also great importance for clinical oncology. The main advantage of 99mTc­Glucoscin is that metabolic tumor imaging with the innovative RP use can be performed using a conventional gamma camera, which significantly reduces the cost of the diagnostic procedure. The present and promising developments of the research teams of the Tomsk Scientific Research Center and the Tomsk Polytechnic University are closely related to theranostics — the use of RPs obtained on the basis of same target compound labeled with different isotopes intended for the diagnosis or therapy of oncological diseases.